Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022)

  • ID: 4463734
  • Report
  • Region: Global
  • 180 Pages
  • Azoth Analytics
1 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Hoffmann
  • La Roche
  • Merck and Co
  • MORE
"Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022) - By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, France, China, India, Japan)"

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Hepatitis B Treatment Market by Type (Therapeutics and Vaccines), By End-User (Male and Female) for the regions (North America, Europe, Asia-Pacific and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan).

Over the recent years, the global Hepatitis B Treatment industry has been driven by the increasing number of patients diagnosed with Chronic Hepatitis B which results in severe complications, rising awareness about the consequences of viral infection, rigorous efforts to eliminate the viral infection, improving surveillance and diagnostic facilities, significant number of drugs in pipeline with better efficacy coupled with emerging vaccines with lower dosage and better effectiveness. Globally, the growth in Hepatitis B Treatment market is driven by backed by growing middle class population group demanding better drugs to improve lifestyle.

According to the research report “Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022) - By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, France, China, India, Japan)”, global market is projected to display a growth represented by a CAGR of 5.30% by value during 2017 - 2022, chiefly driven by increase in healthcare spending and improving access to diagnosis for Chronic Hepatitis B, increasing risk of severe complications due to Hepatitis B virus.

Among the type of treatment, therapeutics accounts for the major market share and anticipated to witness significant growth rate during the forecast period. Among the regions, Asia Pacific is predicted to advance at the highest rate, mainly driven by large population suffering with chronic Hepatitis B virus with unfulfilled need, improving access to healthcare, changing lifestyle and expanding middle class income group.

The report titled, “Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User (Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022) - By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, UK, Germany, France, China, India, Japan)” has covered and analysed the potential of Hepatitis B Treatment Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global Hepatitis B Treatment market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
  • Global Hepatitis B Treatment Market
  • Analysis By Type (Therapeutics and Vaccines)
  • Analysis By End-User (Male and Female)
Regional Markets - North America, Europe, APAC, ROW (Actual Period: 2012-2016, Forecast Period: 2017-2022)
  • By Type (Therapeutics and Vaccines)
  • By End-User (Male and Female)
Country Analysis - United States, Canada, United Kingdom, Germany, France, China, India, Japan (Actual Period: 2012-2016, Forecast Period: 2017-2022)
  • By Type (Therapeutics and Vaccines)
  • By End-User (Male and Female)
Other Report Highlights
  • Market Dynamics - Trends, Drivers, Challenges, Policy and Regulation
  • Company Analysis - Merck and Co; Gilead Sciences; Novartis AG; GlaxoSmithKline, plc; Hoffmann- La Roche; Bristol-Myers Squibb
Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Hoffmann
  • La Roche
  • Merck and Co
  • MORE
1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Hepatitis B Treatment Market: Product Outlook

5. Global Hepatitis B Treatment Market: Growth and Forecast
5.1. Global Hepatitis B Treatment Market, By Value (2012-2016)
5.2. Global Hepatitis B Treatment Market, By Value (2017-2022)
5.3. Global Hepatitis B Treatment Market - By Type, By Value
5.3.1. Global Hepatitis B Treatment Market, By Value, % (2016)
5.3.2. Global Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
5.4. Global Hepatitis B Treatment Market, By Type, By Value (2012-2022)
5.4.1. Therapeutics, By Value (2012-2022)
5.4.2. Vaccines, By Value (2012-2022)
5.5. Global Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
5.5.1. Male, By Value (2012-2022)
5.5.2. Female, By Value (2012-2022)

6. North America Hepatitis B Treatment Market: Growth and Forecast
6.1. North America Hepatitis B Treatment Market, By Value (2012-2016)
6.2. North America Hepatitis B Treatment Market, By Value (2017-2022)
6.3. North America Hepatitis B Treatment Market - By Type, By Value
6.3.1. North America Hepatitis B Treatment Market, By Value, % (2016)
6.3.2. North America Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
6.4. North America Hepatitis B Treatment Market, By Type, By Value (2012-2022)
6.4.1. Therapeutics, By Value (2012-2022)
6.4.2. Vaccines, By Value (2012-2022)
6.5. North America Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
6.5.1. Male, By Value (2012-2022)
6.5.2. Female, By Value (2012-2022)
6.6. North America Hepatitis B Treatment Market: Country Analysis (U.S., Canada)
6.6.1. North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
6.6.2. North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
6.7. U.S. Hepatitis B Treatment Market: Growth and Forecast
6.7.1. U.S. Hepatitis B Treatment Market, By Value (2012-2016)
6.7.2. U.S. Hepatitis B Treatment Market, By Value (2017-2022)
6.8. U.S. Hepatitis B Treatment Market - By Type, By Value
6.8.1. Therapeutics, By Value (2012-2022)
6.8.2. Vaccines, By Value (2012-2022)
6.9. U.S. Hepatitis B Treatment Market - By End-User, By Value
6.9.1. Male, By Value (2012-2022)
6.9.2. Female, By Value (2012-2022)
6.10. Canada Hepatitis B Treatment Market: Growth and Forecast
6.10.1. Canada Hepatitis B Treatment Market, By Value (2012-2016)
6.10.2. Canada Hepatitis B Treatment Market, By Value (2017-2022)
6.11. Canada Hepatitis B Treatment Market - By Type, By Value
6.11.1. Therapeutics, By Value (2012-2022)
6.11.2. Vaccines, By Value (2012-2022)
6.12. Canada Hepatitis B Treatment Market - By End-User, By Value
6.12.1. Male, By Value (2012-2022)
6.12.2. Female, By Value (2012-2022)

7. Europe Hepatitis B Treatment Market: Growth and Forecast
7.1. Europe Hepatitis B Treatment Market, By Value (2012-2016)
7.2. Europe Hepatitis B Treatment Market, By Value (2017-2022)
7.3. Europe Hepatitis B Treatment Market - By Type, By Value
7.3.1. Europe Hepatitis B Treatment Market, By Value, % (2016)
7.3.2. Europe Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
7.4. Europe Hepatitis B Treatment Market, By Type, By Value (2012-2022)
7.4.1. Therapeutics, By Value (2012-2022)
7.4.2. Vaccines, By Value (2012-2022)
7.5. Europe Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
7.5.1. Male, By Value (2012-2022)
7.5.2. Female, By Value (2012-2022)
7.6. Euorpe Hepatitis B Treatment Market: Country Analysis (U.K., Germany, France)
7.6.1. Europe Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
7.6.2. Europe Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
7.7. U.K. Hepatitis B Treatment Market: Growth and Forecast
7.7.1. U.K. Hepatitis B Treatment Market, By Value (2012-2016)
7.7.2. U.K. Hepatitis B Treatment Market, By Value (2017-2022)
7.8. U.K. Hepatitis B Treatment Market - By Type, By Value
7.8.1. Therapeutics, By Value (2012-2022)
7.8.2. Vaccines, By Value (2012-2022)
7.9. U.K. Hepatitis B Treatment Market - By End-User, By Value
7.9.1. Male, By Value (2012-2022)
7.9.2. Female, By Value (2012-2022)
7.10. Germany Hepatitis B Treatment Market: Growth and Forecast
7.10.1. Germany Hepatitis B Treatment Market, By Value (2012-2016)
7.10.2. Germany Hepatitis B Treatment Market, By Value (2017-2022)
7.11. Germany Hepatitis B Treatment Market - By Type, By Value
7.11.1. Therapeutics, By Value (2012-2022)
7.11.2. Vaccines, By Value (2012-2022)
7.12. Germany Hepatitis B Treatment Market - By End-User, By Value
7.12.1. Male, By Value (2012-2022)
7.12.2. Female, By Value (2012-2022)
7.13. France Hepatitis B Treatment Market: Growth and Forecast
7.13.1. France Hepatitis B Treatment Market, By Value (2012-2016)
7.13.2. France Hepatitis B Treatment Market, By Value (2017-2022)
7.14. France Hepatitis B Treatment Market - By Type, By Value
7.14.1. Therapeutics, By Value (2012-2022)
7.14.2. Vaccines, By Value (2012-2022)
7.15. France Hepatitis B Treatment Market - By End-User, By Value
7.15.1. Male, By Value (2012-2022)
7.15.2. Female, By Value (2012-2022)

8. Asia-Pacific Hepatitis B Treatment Market: Growth and Forecast
8.1. Asia-Pacific Hepatitis B Treatment Market, By Value (2012-2016)
8.2. Asia-Pacific Hepatitis B Treatment Market, By Value (2017-2022)
8.3. Asia-Pacific Hepatitis B Treatment Market - By Type, By Value
8.3.1. Asia-Pacific Hepatitis B Treatment Market, By Value, % (2016)
8.3.2. Asia-Pacific Hepatitis B Treatment Market, By Value, % (Forecast 2022F)
8.4. Asia-Pacific Hepatitis B Treatment Market, By Type, By Value (2012-2022)
8.4.1. Therapeutics, By Value (2012-2022)
8.4.2. Vaccines, By Value (2012-2022)
8.5. Asia-Pacific Hepatitis B Treatment Market, By End-User, By Value (2012-2022)
8.5.1. Male, By Value (2012-2022)
8.5.2. Female, By Value (2012-2022)
8.6. Asia-Pacific Hepatitis B Treatment Market: Country Analysis (Japan, China, India)
8.6.1. Asia-Pacific Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
8.6.2. Asia-Pacific Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
8.7. Japan Hepatitis B Treatment Market: Growth and Forecast
8.7.1. Japan Hepatitis B Treatment Market, By Value (2012-2016)
8.7.2. Japan Hepatitis B Treatment Market, By Value (2017-2022)
8.8. Japan Hepatitis B Treatment Market - By Type, By Value
8.8.1. Therapeutics, By Value (2012-2022)
8.8.2. Vaccines, By Value (2012-2022)
8.9. Japan Hepatitis B Treatment Market - By End-User, By Value
8.9.1. Male, By Value (2012-2022)
8.9.2. Female, By Value (2012-2022)
8.10. China Hepatitis B Treatment Market: Growth and Forecast
8.10.1. China Hepatitis B Treatment Market, By Value (2012-2016)
8.10.2. China Hepatitis B Treatment Market, By Value (2017-2022)
8.11. China Hepatitis B Treatment Market - By Type, By Value
8.11.1. Therapeutics, By Value (2012-2022)
8.11.2. Vaccines, By Value (2012-2022)
8.12. China Hepatitis B Treatment Market - By End-User, By Value
8.12.1. Male, By Value (2012-2022)
8.12.2. Female, By Value (2012-2022)
8.13. India Hepatitis B Treatment Market: Growth and Forecast
8.13.1. India Hepatitis B Treatment Market, By Value (2012-2016)
8.13.2. India Hepatitis B Treatment Market, By Value (2017-2022)
8.14. India Hepatitis B Treatment Market - By Type, By Value
8.14.1. Therapeutics, By Value (2012-2022)
8.14.2. Vaccines, By Value (2012-2022)
8.15. India Hepatitis B Treatment Market - By End-User, By Value
8.15.1. Male, By Value (2012-2022)
8.15.2. Female, By Value (2012-2022)

9. ROW Hepatitis B Treatment Market: Growth and Forecast
9.1. ROW Hepatitis B Treatment Market, By Value (2012-2016)
9.2. ROW Hepatitis B Treatment Market, By Value (2017-2022)

10. Market Dynamics
10.1. Increasing prevalence of Liver diseases due to Hepatitis B
10.2. Increasing awareness about the Hepatitis B & HBV
10.3. Rising healthcare expenditure worldwide

11. Market Restraints

12. SWOT Analysis - Hepatitis B Treatment Market

13. Porter’s Five Forces Analysis

14. Policy and Regulations

15. Global Hepatitis B Drugs Pipeline

16. Global Hepatitis B Treatment Market - Competitive Landscape

17. Company Profiles
17.1. Merck and Co
17.2. Gilead Sciences
17.3. Novartis AG
17.4. GlaxoSmithKline, plc
17.5. F.Hoffmann- La Roche
17.6. Bristol-Myers Squibb
17.7. AbbVie Inc

List of Figures
Figure 1: Global Hepatitis B Treatment Market Size, By Value, 2012-2016 (USD Million)
Figure 2: Number of patients with Hepatitis B Virus (HBsAg) infection by WHO region, 2015 (In Million)
Figure 3: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 4: Global Hepatitis B Treatment Market Size, By Value, 2017-2022 (USD Million)
Figure 5: Global Hepatitis B Treatment Market Size, By Type, 2016 (%)
Figure 6: Global Hepatitis B Treatment Market Size, By Type, 2022 (%)
Figure 7: Global Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 8: Global Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 9: Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million)
Figure 10: Global Sales of Viread, By Value, 2015-2016 (USD Million)
Figure 11: Global Hepatitis B Treatment Market Size, By Region, 2016 (%)
Figure 12: Global Hepatitis B Treatment Market Size, By Region, 2022 (%)
Figure 13: North America Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 14: North America GDP, 2012-2015 (USD Trillion)
Figure 15: North America GDP, By Select Country, 2016 (USD Trillion)
Figure 16: Population aged 65 & above, 2012-2016 (% of total)
Figure 17: North America Hepatitis B Treatment Market Size, By Type, 2016 (%)
Figure 18: North America Hepatitis B Treatment Market Size, By Type, 2022 (%)
Figure 19: North America Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 20: North America Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 21: North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total)
Figure 22: North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total)
Figure 23: U.S. Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 24: U.S. Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 25: Reported acute (new) cases of Hepatitis B Virus in U.S., (2012-2015)
Figure 26: Incidences rate of acute Hepatitis B in U.S., By sex (2012-2015)
Figure 27: Incidence of acute Hepatitis B in U.S., By age group, (2012-2015)
Figure 28: U.S. Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 29: U.S. Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 30: Market Share of HBV approved Drugs in U.S., 2016 (% Share)
Figure 31: Canada Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 32: Canada Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 33: Canada Life Expectancy at birth rate (Years), 2012-2015
Figure 34: Prevalence of Hepatitis B in Canada, (Patients per 100,000 (2012-2016)
Figure 35: Number of Hepatitis B Patients, Canada, (2013-2016)
Figure 36: Prevalence of Hepatitis B among Male population, Canada, (Patients per 100,000) (2012-2016)
Figure 37: Prevalence of Hepatitis B among Female population, Canada, (Patients per 100,000) (2012-2016)
Figure 38: Canada Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 39: Canada Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 40: Europe Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million)
Figure 41: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 42: European Union Life Expectancy at birth rate (Years), 2012-2015
Figure 43: Reported Hepatitis B Cases, Number & Rate per 100,000 populations, EU/EEA, 2012-2015
Figure 44: Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015
Figure 45: Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015
Figure 46: Europe Hepatitis B Treatment Market Size, By Type, 2016 (%)
Figure 47: Europe Hepatitis B Treatment Market Size, By Type, 2022 (%)
Figure 48: Europe Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million)
Figure 49: Europe Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
Figure 50: Europe Hepatitis B Treatment, Country Share, 2016 (% of Total)
Figure 51: Europe Hepatitis B Treatment, Country Share, 2022 (% of Total)
Figure 52: U.K. Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 53: U.K. Population 65 Years & Above (% of Total), 2012-2016
Figure 54: U.K. Life Expectancy at birth rate (Years), 2012-2015
Figure 55: U.K. Women Population, 2012-2016
Figure 56: U.K., Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 57: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 58: Number of Hepatitis B Patients, (2013-2016)
Figure 59: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 60: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 61: U.K. Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 62: U.K. Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 63: Germany Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 64: Germany Population 65 Years & Above (% of Total), 2012-2016
Figure 65: Germany Life Expectancy at birth rate (Years), 2012-2015
Figure 66: Germany Women Population, 2012-2016
Figure 67: Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)
Figure 68: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 69: Number of Hepatitis B Patients, (2013-2016)
Figure 70: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 71: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 72: Germany Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 73: Germany Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 74: France Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 75: France Population 65 Years & Above (% of Total), 2012-2016
Figure 76: France Life Expectancy at birth rate (Years), 2012-2015
Figure 77: France Women Population, 2012-2016
Figure 78: France Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 79: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 80: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 81: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 82: France Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 83: France Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 84: Asia-Pacific Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 85: Mortality due to Viral Hepatitis in South-East Asia region, 2015
Figure 86: Asia-Pacific Hepatitis B Treatment Size, By Type, 2016 (%)
Figure 87: Asia-Pacific Hepatitis B Drug Market Size, By Type, 2022 (%)
Figure 88: Asia-pacific Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 89: Asia-Pacific Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 90: Asia-Pacific Hepatitis B Treatment, Country Share, 2016 (% of Total)
Figure 91: Asia-Pacific Hepatitis B Treatment, Country Share, 2022 (% of Total)
Figure 92: Japan Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 93: Japan Population 65 Years & Above (% of Total), 2012-2016
Figure 94: Japan Life Expectancy at birth rate (Years), 2012-2015
Figure 95: Japan, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 96: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 97: Number of Hepatitis B Patients, 2013-2016)
Figure 98: Prevalence of Hepatitis B among Male population (Patients per 100,000 (2012-2016)
Figure 99: Prevalence of Hepatitis B among Female population (Patients per 100,000 (2012-2016)
Figure 100: Japan Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 101: Japan Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 102: China Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 103: China Population 65 Years & Above (% of Total), 2012-2016
Figure 104: China Life Expectancy at birth rate (Years), 2012-2015
Figure 105: China Women Population, 2012-2016
Figure 106: China Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 107: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 108: Number of Hepatitis B Patients, 2013-2016)
Figure 109: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 110: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 111: China Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 112: China Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 113: India Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 114: India Population 65 Years & Above (% of Total), 2012-2016
Figure 115: India Life Expectancy at birth rate (Years), 2012-2015
Figure 116: India Women Population, 2012-2016
Figure 117: India Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 118: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016)
Figure 119: Number of Hepatitis B Patients, 2013-2016)
Figure 120: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016)
Figure 121: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016)
Figure 122: India Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
Figure 123: India Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million)
Figure 124: ROW Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million)
Figure 125: Prevalence of Hepatitis B in Brazil (Patients per 100,000 (2012-2016)
Figure 126: Number of Hepatitis B Patients in Brazil, (2013-2016)
Figure 127: Prevalence of Hepatitis B among Male population, in Brazil (Patients per 100,000) (2012-2016)
Figure 128: Prevalence of Hepatitis B among Female population in Brazil (Patients per 100,000) (2012-2016)
Figure 129: Prevalence of Hepatitis B in South Africa (Patients per 100,000 (2012-2016)
Figure 130: Number of Hepatitis B Patients in South Africa, (2013-2016)
Figure 131: Prevalence of Hepatitis B among Male population, in South Africa (Patients per 100,000) (2012-2016)
Figure 132: Prevalence of Hepatitis B among Female population (Patients per 100,000), in South Africa (2012-2016)
Figure 133: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 134: Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million)
Figure 135: Global Sales of Viread, By, Region, By Value, 2015-2016 (USD Million)
Figure 136: Merck & Co., Net Sales, 2012-2016 (In million USD)
Figure 137: Merck & Co, Net Sales of Gardasil/Gardasil 9, 2012-2016 (In million USD)
Figure 138: Merck & Co., Net Sales, By Geographic Location, % Share 2016
Figure 139: Merck & Co., Net Revenue, By Business Segment, % Share 2016
Figure 140: Gilead Sciences Annual Revenue, 2014-2016 (USD Million)
Figure 141: Gilead Sciences HBV Product Sales, 2014-2016 (USD Million)
Figure 142: Gilead Sciences Revenue by Geographical, 2016 (%)
Figure 143: Gilead Sciences Product Sales, 2016 (%)
Figure 144: Novartis Annual Revenue, 2014-2016 (USD Million)
Figure 145: Innovative Medicine Net Sales, By Business Unit 2016 (%)
Figure 146: Novartis Sales, By Region, 2016 (%)
Figure 147: Novartis Sales, By Segment 2016 (%)
Figure 148: GlaxoSmithKline Annual Revenue, 2014-2016 (USD Million)
Figure 149: Sales from Hepatitis Vaccination, GlaxoSmithKline, 2015 - 2016 (USD Million)
Figure 150: Glaxosmithkline Sales, By Region, 2016 (%)
Figure 151: Glaxosmithkline, Sales, By Segment 2016 (%)
Figure 152: F. Hoffmann-La Roche Ltd Annual Revenue, 2014-2016 (USD Million)
Figure 153: F. Hoffmann-La Roche Ltd Segmental Break Up, By Revenue, By Business Division, 2016 (%)
Figure 154: F. Hoffmann-La Roche Ltd Geographical Break Up, By Revenue, 2016 (%)
Figure 155: Bristol-Myers Squibb Company Annual Revenue, 2014-2016 (USD Million)
Figure 156: Bristol-Myers Squibb Company Segmental Break Up, By Revenue, By Products, 2016 (%)
Figure 157: Bristol-Myers Squibb Company Geographical Break Up, By Revenue, 2016 (%)
Figure 158: Baraclude (entecavir), Annual Revenue, 2014-2016 (USD Million)
Figure 159: Baraclude (entecavir), Segmental Break Up, By geographical segment, 2016 (%)
Figure 160: AbbVie Revenue, Segmental Break Up, 2016
Figure 161: AbbVie Revenue, Geographical Break Up, 2016

List of Tables
Table A: Causes of Hepatitis B
Table B: HBV Approved Therapies
Table C: Globally Approved HBV Monovalent Vaccines
Table D: Compounds in development for chronic Hepatitis B
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Merck and Co
  • Gilead Sciences
  • Novartis AG
  • GlaxoSmithKline plc
  • Hoffmann
  • La Roche
  • Bristol-Myers Squibb
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll